Atara Biotherapeutics, Inc. announced that on June 1, 2023, Beth Seidenberg, M.D., notified the Company, of her resignation from the Board of Directors of the Company, effective immediately. Dr. Seidenberg indicated her departure from the Board was to pursue other activities. In addition, effective as of June 2, 2023, the Board, in accordance with Section 16 of the Company's Second Amended and Restated Bylaws, reduced the number of directors on the Board from eight to seven directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6998 USD | +0.94% | +9.34% | +36.47% |
May. 20 | Sector Update: Health Care Stocks Ease Monday Afternoon | MT |
May. 20 | Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.47% | 84.27M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.58% | 21.97B | |
-4.55% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors